Jonas Oldgren Selected Research

Warfarin (Coumadin)

3/2024	Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.
1/2022	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
12/2021	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial.
8/2021	Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
7/2021	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials).
1/2021	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
11/2020	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
7/2020	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial.
1/2020	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
1/2020	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonas Oldgren Research Topics

Disease

97	Atrial Fibrillation 03/2024 - 02/2008
70	Hemorrhage 01/2023 - 03/2007
66	Stroke (Strokes) 03/2024 - 02/2008
25	Myocardial Infarction 02/2024 - 10/2004
23	Embolism (Embolus) 01/2022 - 09/2009
15	Heart Failure 02/2024 - 01/2016
13	Ischemic Stroke 03/2024 - 07/2012
11	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 02/2004
10	Acute Coronary Syndrome 01/2021 - 03/2007
9	Thrombosis (Thrombus) 01/2022 - 01/2007
7	Inflammation (Inflammations) 01/2023 - 08/2008
6	Neoplasms (Cancer) 01/2018 - 05/2013
5	Chronic Renal Insufficiency 01/2022 - 05/2013
5	ST Elevation Myocardial Infarction 08/2021 - 02/2008
5	Chest Pain (Chest Pains) 02/2010 - 10/2004
4	Cardiovascular Diseases (Cardiovascular Disease) 09/2021 - 01/2018
3	Type 2 Diabetes Mellitus (MODY) 12/2023 - 01/2019
2	Diabetes Mellitus 12/2023 - 12/2019
2	Body Weight (Weight, Body) 12/2023 - 01/2021
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2021
2	Necrosis 01/2022 - 08/2005
2	Vascular Calcification 11/2021 - 12/2020
2	Fibrosis (Cirrhosis) 12/2020 - 01/2017
2	Ischemia 12/2020 - 01/2018
2	COVID-19 12/2020 - 11/2020
2	Out-of-Hospital Cardiac Arrest 04/2020 - 01/2019
2	Hypertension (High Blood Pressure) 01/2020 - 09/2010
2	Liver Diseases (Liver Disease) 01/2018 - 01/2018
2	Confusion (Bewilderment) 01/2018 - 01/2018
2	Death (Near-Death Experience) 01/2018 - 02/2012
2	Thromboembolism 03/2016 - 03/2015
2	Pulmonary Embolism 12/2015 - 02/2012
2	Infarction (Infarctions) 08/2008 - 02/2008
1	Cardiomyopathies (Cardiomyopathy) 01/2023
1	Cerebral Hemorrhage 10/2022
1	Dementia (Dementias) 01/2022

Drug/Important Bio-Agent (IBA)

49	Warfarin (Coumadin)FDA LinkGeneric 03/2024 - 09/2009
46	Dabigatran FDA Link 01/2022 - 09/2009
33	AnticoagulantsIBA 10/2022 - 02/2008
29	Biomarkers (Surrogate Marker)IBA 03/2024 - 08/2005
21	Vitamin K FDA Link 10/2022 - 05/2009
20	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2021 - 03/2007
17	Clopidogrel (Plavix)FDA Link 08/2021 - 01/2007
13	apixabanIBA 03/2024 - 12/2013
13	N(4)-oleylcytosine arabinosideIBA 10/2022 - 05/2013
10	pro-brain natriuretic peptide (1-76)IBA 01/2023 - 04/2012
10	TicagrelorIBA 08/2021 - 10/2017
9	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2023 - 04/2012
8	Troponin IIBA 01/2019 - 10/2004
6	Cystatin CIBA 01/2022 - 08/2008
6	TroponinIBA 01/2020 - 02/2004
5	dapagliflozinIBA 02/2024 - 01/2019
5	CreatinineIBA 01/2023 - 03/2014
5	Troponin T (Troponin T1)IBA 01/2022 - 06/2016
5	Growth Differentiation Factor 15IBA 11/2021 - 01/2017
5	Heparin (Liquaemin)FDA LinkGeneric 01/2018 - 02/2004
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 02/2013
4	fibrin fragment D (D-dimer)IBA 11/2017 - 03/2007
4	AntithrombinsIBA 11/2011 - 02/2004
3	RivaroxabanIBA 01/2022 - 12/2013
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 12/2015
3	Fondaparinux (Arixtra)FDA Link 02/2015 - 02/2008
2	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 03/2024 - 01/2023
2	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2021
2	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2022 - 12/2013
2	Trefoil Factor-3IBA 01/2022 - 12/2020
2	darapladibIBA 01/2022 - 01/2021
2	N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA 12/2021 - 10/2017
2	omega-Chloroacetophenone (Mace)IBA 01/2018 - 06/2013
2	Thrombin FDA Link 11/2017 - 02/2004
2	edoxabanIBA 01/2017 - 01/2017
2	C-Reactive ProteinIBA 01/2017 - 12/2015
2	trans-crotonin (CTN)IBA 06/2016 - 05/2016
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 09/2010 - 02/2008
2	Dalteparin (Dalteparin Sodium)FDA Link 09/2008 - 03/2008
2	ximelagatran (Exanta)IBA 02/2008 - 03/2007
2	MyoglobinIBA 08/2005 - 10/2004
2	MB Form Creatine KinaseIBA 08/2005 - 10/2004
1	Angiopoietin-2IBA 01/2023
1	Fibroblast Growth Factor-23IBA 01/2022
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2022
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2022
1	Factor Xa (Coagulation Factor Xa)IBA 01/2022
1	Factor XIa (Coagulation Factor XIa)IBA 01/2022
1	CathepsinsIBA 01/2022
1	CalciumIBA 01/2022
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2022
1	Factor Xa InhibitorsIBA 01/2022
1	Dronedarone FDA Link 01/2022
1	Anti-Arrhythmia AgentsIBA 01/2022

Therapy/Procedure

67	Therapeutics 12/2023 - 02/2008
24	Percutaneous Coronary Intervention 01/2022 - 01/2007
9	Electric Countershock (Cardioversion) 01/2018 - 01/2011
6	Stents 01/2021 - 01/2007
3	Drug Therapy (Chemotherapy) 11/2022 - 01/2018
2	Vascular Surgical Procedures 11/2022 - 10/2022
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 11/2009
2	Secondary Prevention 09/2017 - 12/2013
2	Thrombolytic Therapy 09/2010 - 02/2008
1	Catheter Ablation 12/2023